Liqrev (Sildenafil Citrate) Patent Expiration, LOE Window & CMS Spending

Liqrev (Sildenafil Citrate) by Cmp: FDA Orange Book LOE 2038-12-24, 37 AB generics, $154K 2024 CMS Part D & Medicaid spend, and $1,895 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCmp
FDA Application & PathwayN214952 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2038-12-24
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors37
2024 CMS Total Public Spend$154K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$154K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,895 intro WAC)